WO2017156514A3 - Methods and agents for modulating cellular metabolism and treating cancer - Google Patents
Methods and agents for modulating cellular metabolism and treating cancer Download PDFInfo
- Publication number
- WO2017156514A3 WO2017156514A3 PCT/US2017/021993 US2017021993W WO2017156514A3 WO 2017156514 A3 WO2017156514 A3 WO 2017156514A3 US 2017021993 W US2017021993 W US 2017021993W WO 2017156514 A3 WO2017156514 A3 WO 2017156514A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- cellular metabolism
- agents
- treating cancer
- modulating cellular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Methods are provided for modulating cellular metabolism by exposing cells to an agent that reduces translation of MYC dependent mRNA transcripts. Such methods and agents are useful for treatment of cancer, and altering cellular metabolism.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662307193P | 2016-03-11 | 2016-03-11 | |
US62/307,193 | 2016-03-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017156514A2 WO2017156514A2 (en) | 2017-09-14 |
WO2017156514A3 true WO2017156514A3 (en) | 2017-10-19 |
Family
ID=59789747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/021993 WO2017156514A2 (en) | 2016-03-11 | 2017-03-12 | Methods and agents for modulating cellular metabolism and treating cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017156514A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113599524B (en) * | 2021-09-02 | 2023-05-02 | 中国医学科学院肿瘤医院 | Application of HNRNPC and RBMX as targets in preparation of products for treating small cell lung cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110064739A1 (en) * | 2008-03-28 | 2011-03-17 | Borlak Juergen | Medicament, compositions, and substances for treating and identifying adenocarcinoma of the lung |
-
2017
- 2017-03-12 WO PCT/US2017/021993 patent/WO2017156514A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110064739A1 (en) * | 2008-03-28 | 2011-03-17 | Borlak Juergen | Medicament, compositions, and substances for treating and identifying adenocarcinoma of the lung |
Non-Patent Citations (1)
Title |
---|
ROMAN ET AL.: "mTFE3, an X-linked transcriptional activator containing basic helix-loop-helix and zipper domains, utilizes the zipper to stabilize both DNA binding and multimerization", MOL CELL BIOL., vol. 12, no. 2, February 1992 (1992-02-01), pages 817 - 827, XP055428974 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017156514A2 (en) | 2017-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020012028A (en) | Methods and compositions for treating cancer. | |
CL2019000511A1 (en) | Inhibitors of cellular metabolic processes. | |
BR112018067368A2 (en) | anti-cd73 antibody combination therapy | |
MX2020012797A (en) | Anti-pvrig/anti-tigit bispecific antibodies and methods of use. | |
CL2018003316A1 (en) | Compounds for the inhibition of k-ras and for the treatment of cancer. (divisional application 201702786) | |
MX2023007841A (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy. | |
MX2018005315A (en) | Compositions and methods for treatment of cancer. | |
PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
MX2017011630A (en) | Compositions and methods for treating rosacea and acne. | |
EP4339287A3 (en) | Modified cells and methods of therapy | |
EA201990296A1 (en) | ANTIBODIES AGAINST SIGLEC-7 FOR CANCER TREATMENT | |
WO2017216772A3 (en) | Methods and compositions for treating breast and prostate cancer | |
BR112018003269A2 (en) | anti-dll3 drug-antibody conjugates and methods of use | |
WO2014164704A3 (en) | Compounds and compositions for the treatment of cancer | |
MX2021005398A (en) | Anti-cd33 immune cell cancer therapy. | |
MX2017010595A (en) | Methods, compositions, and kits for treatment of cancer. | |
EP3581182A4 (en) | Combination treating prostate cancer, pharmaceutical composition and treatment method | |
JOP20190285A1 (en) | Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia | |
MX2019010040A (en) | Compositions and methods for treatment of cancer. | |
EP3666888A4 (en) | Method for activating t cells for cancer treatment | |
WO2016160621A3 (en) | Nk-92 cells in combination therapy with cancer drugs | |
PH12017501879A1 (en) | Methods for treating cancer | |
WO2017123568A3 (en) | Methods for the treatment of myeloid derived suppressor cells related disorders | |
IL268163A (en) | Methods, compositions, and kits for treatment of cancer | |
PH12020551543A1 (en) | Therapeutic modulators of the reverse mode of atp synthase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17764273 Country of ref document: EP Kind code of ref document: A2 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 31.01.2019) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17764273 Country of ref document: EP Kind code of ref document: A2 |